Is CTRE a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Acquisitions at a wide spread over cost of capital, with revenue (ttm) at ~$571 million, with Q2 2026 at ~$161 million versus ~$113 million a year earlier. The bear case rests on tenant concentration is the sharpest risk: Ensign accounts for ~21% of annualized rent and PACS Group ~10%, and PACS has been contending with a federal investigation into its reimbursement and referral practices plus shareholder litigation, so a single operator's trouble can travel straight into CareTrust's rent roll. Analysts covering it are spread from $43.00 to $49.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Tenant concentration is the sharpest risk: Ensign accounts for ~21% of annualized rent and PACS Group ~10%, and PACS has been contending with a federal investigation into its reimbursement and referral practices plus shareholder litigation, so a single operator's trouble can travel straight into CareTrust's rent roll. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $43.00, +9.8% from the $39.16 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Acquisitions at a wide spread over cost of capital. CareTrust closed ~$900 million of investments in the second quarter at a ~8.9% blended stabilized yield, its largest non-M&A quarter, plus ~$308 million after quarter end at ~7.8%, taking year-to-date deployment to ~$1.5 billion at ~8.7%. The most optimistic analyst target on CTRE is $49.00, +25.1% from the $39.16 price. That figure is only reachable if this thesis works close to its best case.

Tenant concentration is the sharpest risk: Ensign accounts for ~21% of annualized rent and PACS Group ~10%, and PACS has been contending with a federal investigation into its reimbursement and referral practices plus shareholder litigation, so a single operator's trouble can travel straight into CareTrust's rent roll. Reimbursement policy sits underneath everything, since operators are paid mostly by Medicare and Medicaid, and the 2025 federal law steps the state provider tax cap down from 6% to 3.5% by fiscal 2032 in Medicaid expansion states while individual states debate their own rate cuts. The growth model itself is a dependency: mid-teens FFO per share growth requires continuously issuing equity and finding deals at 8%-plus yields, and if either the equity window closes or cap rates compress, the growth rate resets to escalators alone. Interest rates cut both ways, raising the cost of the debt CareTrust has not yet drawn and setting the yield investors demand on the stock. The UK portfolio adds currency exposure, with guidance explicitly assuming no material move in the GBP to USD rate. The most pessimistic published target is $43.00, +9.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Net-lease owner of skilled nursing and seniors housing property, leased to operators such as Ensign and PACS, carrying almost no leverage.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Acquisitions at a wide spread over cost of capital) stalling in the reported numbers rather than in the narrative, the risk above (tenant concentration is the sharpest risk: Ensign accounts for ~21% of annualized rent and PACS Group ~10%, and PACS has been contending with a federal investigation into its reimbursement and referral practices plus shareholder litigation, so a single operator's trouble can travel straight into CareTrust's rent roll) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

CareTrust owns the real estate, not the care business. Its portfolio is mostly skilled nursing facilities plus senior housing, assisted living and multi-service campuses across roughly 30 US states and, following the 2025 purchase of Care REIT plc, the United Kingdom. Third-party operators run the facilities under long-term triple-net leases and pay taxes, insurance and maintenance themselves. CareTrust also holds a book of mortgage and mezzanine loans to operators.

REIT accounting requires large depreciation charges on buildings that generally hold or grow in value, so GAAP net income systematically understates cash generation. Funds from operations adds depreciation back; funds available for distribution goes further and subtracts recurring capital costs and non-cash rent. CareTrust reported ~$0.38 of diluted EPS in the second quarter of 2026 against ~$0.51 of normalized FFO per share, and it guides and pays the dividend off the latter.

Concentrated, though less than it once was. The Ensign Group, from which CareTrust was spun off in 2014, is around 21% of annualized rent, PACS Group is roughly 10% and Priority Management Group about 7%. The top ten operators together account for roughly 69% of rent, leaving about 31% spread across smaller regional operators. Ensign's share has fallen steadily as the portfolio has grown, but it remains the single largest exposure to watch.